Stocktwits on MSN

Cingulate stock jumps overnight: US Patent Office clears ADHD drug filing ahead of May FDA catalyst

The USPTO cleared a patent filed in November 2023, with a status indicating it has been approved and the patent is expected ...
Benzinga.com

Cingulate Shares Are Trading By More Than 200% Friday: What You Need To Know

Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...
Seeking Alpha

Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application

KANSAS CITY, Kan., July 09, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (CING) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
Seeking Alpha

Cingulate Provides Management Team Update

KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CING) The Board of Directors of Cingulate Inc. (CING) (“Cingulate”) announced that it has placed Chairman and Chief Executive Officer, ...
Business Insider

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced ...
Nasdaq

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

KANSAS CITY, Kan., June 29, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...